FGFR4 signaling couples to Bim and not Bmf to discriminate subsets of alveolar rhabdomyosarcoma cells

International Journal of Cancer

Volumn 135, Issue 7, 2014, Pages 1543-1552

  Wachtel, Marco ^a   Rakic, Jelena ^a   Okoniewski, Michal ^b   Bode, Peter ^c   Niggli, Felix ^a   Schäfer, Beat W ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b FUNCTIONAL GENOMICS CENTER ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

alveolar rhabdomyosarcoma; BH3 only proteins; FGFR4; tumor heterogeneity

Indexed keywords

AEW 541; ANTINEOPLASTIC AGENT; BGJ 398; BH3 PROTEIN; BIM PROTEIN; DACTOLISIB; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PAIRED BOX TRANSCRIPTION FACTOR; PD 184325; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BMF; PROTEIN KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

ALVEOLAR SOFT PART SARCOMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL HETEROGENEITY; CELL SUBPOPULATION; CELL SURVIVAL; CELL TYPE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA CELL; SIGNAL TRANSDUCTION; TUMOR BIOPSY;

ALVEOLAR RHABDOMYOSARCOMA; BH3-ONLY PROTEINS; FGFR4; TUMOR HETEROGENEITY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA, ALVEOLAR; RNA, MESSENGER; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84904465899     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28800     Document Type: Article

References (33)

1. Duffy MJ, O'Donovan N, Crown J,. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011; 37: 151-9.
2. Almendro V, Marusyk A, Polyak K,. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013; 8: 277-302.
3. Davicioni E, Finckenstein FG, Shahbazian V, et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66: 6936-46.
4. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004; 64: 5539-45.
5. Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28: 2151-8.
6. Walter D, Satheesha S, Albrecht P, et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One 2011; 6: e19506.
7. Sana J, Zambo I, Skoda J, et al. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol (Amst) 2011; 34: 303-18.
8. Pressey JG, Haas MC, Pressey CS, et al. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer 2013; 60: 45-52.
9. Ognjanovic S, Linabery AM, Charbonneau B, et al. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer 2009; 115: 4218-26.
10. Cao L, Yu Y, Bilke S, et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010; 70: 6497-508.
11. Paulson V, Chandler G, Rakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 2011; 50: 397-408.
12. Taylor JGT, Cheuk AT, Tsang PS, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 2009; 119: 3395-407.
13. Turner N, Grose R,. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10: 116-29.
14. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-8.
15. Amstutz R, Wachtel M, Troxler H, et al. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res 2008; 68: 3767-76.
16. Wilson CL, Miller CJ,. Simpleaffy: a BioConductor package for affymetrix quality control and data analysis. Bioinformatics 2005; 21: 3683-5.
17. Sims AH, Smethurst GJ, Hey Y, et al. The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets-improving meta-analysis and prediction of prognosis. BMC Med Genom 2008; 1: 42.
18. Li C, Wong WH,. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98: 31-6.
19. Oesch S, Walter D, Wachtel M, et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther 2009; 8: 1838-45.
20. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65: 3868-76.
21. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009; 69: 7662-71.
22. Youle RJ, Strasser A,. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
23. Wiggins CM, Johnson M, Cook SJ,. Refining the minimal sequence required for ERK1/2-dependent poly-ubiquitination and proteasome-dependent turnover of BIM. Cell Signal 2010; 22: 801-8.
24. Zha J, Harada H, Yang E, et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619-28.
25. Scheid MP, Schubert KM, Duronio V,. Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem 1999; 274: 31108-13.
26. Qi XJ, Wildey GM, Howe PH,. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 2006; 281: 813-23.
27. del Peso L, Gonzalez-Garcia M, Page C, et al. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-9.
28. Grass B, Wachtel M, Behnke S, et al. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology 2009; 54: 873-9.
29. Liu J, Guzman MA, Pezanowski D, et al. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma. Mod Pathol 2011; 24: 1327-35.
30. Crose LE, Etheridge KT, Chen C, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012; 18: 3780-90.
31. Happo L, Strasser A, Cory S,. BH3-only proteins in apoptosis at a glance. J Cell Sci 2012; 125: 1081-1087.
32. Shao Y, Aplin AE,. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis 2012; 3: e253.
33. Wachtel M, Runge T, Leuschner I, et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006; 24: 816-22.